Gain Therapeutics, Inc.
GANXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeGain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company carries a $78.6M market cap, placing it firmly in the micro-cap category. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Market Cap
$78.6M
Beta
0.21
P/E (TTM)
—
P/E (Fwd)
-3.29
EPS (TTM)
$-0.50
EPS (Fwd)
$-0.55
ROE
-268.3%
ROA
-95.5%
Cash
$13.1M
Total Debt
$609,874
Free CF
-$11.1M
52W Change
4.0%
Annual Financials
Cash vs Debt
Where GANX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, GANX finished 7.25% below its 150-day moving average ($1.93) and 17.89% below its 200-day moving average ($2.18). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GANX overbought or oversold?
At the September 3, 2026 close, GANX's RSI(14) was 22.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $13.1M in cash comfortably exceeding the $610K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$11.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -268.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $140K (2022) to $0 (2025), a 100% decline worth watching.
GANX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, GANX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Gain Therapeutics, Inc.'s trajectory.